Media

Topical Estrogen Therapy Yields Significant Cost Savings in Preventing Recurrent UTIs Among Postmenopausal Women - Rachael Sussman & Charlotte Houston

Details
Charlotte Houston and Rachael Sussman discuss their recent work published in Urology Practice, focusing on the cost-savings analysis of topical estrogen therapy for preventing UTIs in post-menopausal women. The research reveals significant savings—between $3,600 to $5,400 per patient annually—when using these therapies, underscoring not only their effectiveness but also their economic efficiency....

NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay

Details
Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. With a multi-institutional...

Gender-Based Disparity Exists in the Surgical Experience of Female and Male Urology Residents - Kathryn Marchetti

Details
Katie Marchetti delves into gender disparities within the surgical experience of male and female urology residents, a topic of her recent publication in the Gold Journal. Despite increasing representation of women in medicine, urology training reveals significant gender disparities in mentorship, academic development, and notably, surgical case logs. Through analysis of data from 13 ACGME accredit...

USMLE Score Cutoffs Disproportionately Impact Underrepresented Urology Applicants - Alain Kaldany

Details
Ruchika Talwar hosts Alain Kaldany for a discussion on his study of USMLE cutoffs and their impact on diversity in urology residency matches. Dr. Kaldany shares insights into how USMLE Step 1 and 2 scores, traditionally used as screening tools in urology residency applications, may disproportionately disadvantage underrepresented applicants without correlating to clinical performance. Highlighting...

How Long is Recovery After TURBT? Patient-Reported Outcomes Provide Answers - Marshall Strother

Details
Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. Findings reveal most patients experience mild symptoms post-surgery, with a significa...

Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia

Details
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the multidi...

Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood

Details
Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis and Sarah Wood. Dr. Davis describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Dr. Wood outlines her role in educating and managing patients...

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes - Nicholas Zorko

Details
Nicholas Zorko discusses the promising role of natural killer (NK) cells in prostate cancer, described his team’s study published in Prostate Cancer and Prostatic Diseases. The research reveals that increased NK cell infiltration in prostate tumors correlates with improved patient outcomes, suggesting NK cells as a potential next frontier in cellular therapies for prostate cancer. The study utiliz...

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen dissect the EV-302 trial, presenting enfortumab vedotin and pembrolizumab as a first-line treatment for advanced urothelial cancer. This trial, marked by its publication in The New England Journal of Medicine, challenges the four-decade reign of platinum-based chemotherapy, revealing its limitations, particularly a median overall survival of merely 15-16 months. Dr....

Clearing the Smoke: Underreporting of Smoking Status in Bladder Cancer Clinical Trials - Hannah Kay & Marc Bjurlin

Details
Ruchika Talwar hosts Hannah Kay and Marc Bjurlin to unravel their study on the sparse reporting of smoking status in bladder cancer trials. Their research, "Clearing the Smoke," highlights a concerning discrepancy: only 41.2% of bladder cancer trials over the past decade reported participants' smoking status, starkly contrasting with higher reporting rates in lung cancer trials. This gap suggests...